Wave Life Sciences Ltd.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Paul Bolno
- Full Time Employees
- 317
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Marina One East Tower Singapore CE Singapore 018936
- IPO Date
- Nov 11, 2015
- CIK
- 0001631574
- Website
- wavelifesciences.com
- Similar Companies
- Business
- Wave Life Sciences Ltd. (Nasdaq: WVE) is a clinical-stage biotechnology company that designs, develops and commercializes stereopure ribonucleic acid (RNA) medicines for genetically defined diseases utilizing its proprietary PRISM platform; the platform combines multiple RNA-targeting modalities including RNA editing via AIMer technology, antisense silencing, and RNA interference with chemistry innovation and human genetics insights to create differentiated therapeutics. Core programs target alpha-1 antitrypsin deficiency (AATD) with WVE-006, a GalNAc-conjugated RNA editing oligonucleotide licensed exclusively to GSK; obesity with WVE-007, a GalNAc-siRNA targeting INHBE that demonstrated up to 85% Activin E reductions in the INLIGHT trial supporting potential once- or twice-yearly dosing for fat loss and muscle preservation; Duchenne muscular dystrophy (DMD) with WVE-N531, an exon-skipping oligonucleotide advancing toward a 2026 New Drug Application filing; and Huntington's disease (HD) with WVE-003, which received supportive FDA feedback including orphan drug designation. The company operates primarily in the genetic medicines industry serving patients with rare and prevalent disorders such as AATD, DMD, HD and obesity through wholly owned and partnered programs. Founded in 2012 and headquartered in Singapore with key research and development operations in Cambridge, Massachusetts, Wave maintains a UK subsidiary focused on pharmaceutical manufacturing. Recent developments include positive third-quarter 2025 clinical data for WVE-007 and WVE-006 validating RNA editing and RNAi capabilities; GSK's acquisition of additional shares worth $22.3 million in September 2024 increasing its ownership; termination of the Takeda collaboration in October 2024 allowing Wave to regain full control of its HD program; preclinical advancements supporting WVE-007 as monotherapy, GLP-1 add-on or maintenance therapy; and a cash position extending runway into 2027.
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation
Does Wave Life Sciences (WVE) Have the Potential to Rally 294.66% as Wall Street Analysts Expect?
Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases
Wave Life Sciences (WVE) Upgraded to Buy: Here's Why
Wave Life Sciences Ltd. (WVE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Wave Life Sciences to Present at Upcoming Investor Conferences
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter
Wave Life Sciences Ltd. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses
Wave Life Sciences: 'Strong Buy' On DMD NDA Filing WVE-N531 And Released AATD Data
Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1
Wave Life Sciences Ltd. (WVE) Shareholder/Analyst Call Transcript
Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing
Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Alibaba, Boston Scientific, Brown-Forman, Charter Communications, Franklin Resources, Spotify, T-Mobile, and More
Wave Life Sciences (WVE) Reports Q1 Loss, Beats Revenue Estimates
Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026
Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States
Wave Life Sciences Announces Proposed Redomiciliation to the United States